FEDERAL COURT OF AUSTRALIA
Australian Competition and Consumer Commission v Homeopathy Plus! Australia Pty Limited [2014] FCA 1412
Citation: Australian Competition and Consumer Commission v Homeopathy Plus! Australia Pty Limited [2014] FCA 1412 Parties: AUSTRALIAN COMPETITION AND CONSUMER COMMISSION v HOMEOPATHY PLUS! AUSTRALIA PTY LIMITED and FRANCES MERCIA SHEFFIELD File number: NSD 256 of 2013 Judge: PERRY J Date of judgment: 22 December 2014 Catchwords: CONSUMER LAW – Whether misleading, deceptive or false representations made on website about the effectiveness of whooping cough vaccine – Means of assessing efficacy and effectiveness of vaccine – Evidence based medicine – Bearing of context on characterisation of representations – Whether representations misleading, deceptive or false when read in context of an epidemic – Whether representation that vaccine was “short-lived” was misleading, deceptive or false given vaccine’s propensity to wane over time.
CONSUMER LAW – Whether misleading, deceptive or false representations made about the effectiveness of homeopathic treatments for the prevention of whooping cough – Whether representations about effectiveness of homeopathic treatments fall to be assessed against a homeopathic epistemological framework or orthodox medical science – Whether representations imply a reasonable basis in medical science.
CONSUMER LAW – Whether disclaimers erase misleading, deceptive and false nature of representations – Where disclaimer did not clearly bring the true position to the public’s attention.
CONSUMER LAW – Whether representations made in trade or commerce – Whether or not carried on for profit –
Where representations said to be contribution to public debate or educational – Whether conduct has requisite commercial or trading character – Where conduct has dual character – Where representations not presented overtly in form of an advertisement.EVIDENCE – Where expert reports do not comply with s 79 of the Evidence Act 1995 (Cth) – Precondition to admissibility of expert evidence – Failure to provide reasons for opinion and demonstrate connection with specialised knowledge – Whether the manner in which material might be presented in the field of expertise is relevant – Duty of legal representatives to ensure expert reports comply with rules of evidence and court practice directions.
Legislation: Australian Consumer Law, ss 4, 6(3)(a),(b), 18, 29(1)(a),(b),(g)
Competition and Consumer Act 2010 (Cth) s 6
Corporations Act 2001 (Cth), ss 180, 181, 182
Evidence Act 1995 (Cth), ss 79 and 190(3)(b)
National Health and Medical Research Council Act 1992 (Cth) ss 3(1), 7(1)
Therapeutic Goods Act 1989 (Cth) ss 3(1), 4, 19, 19A, 19D(1), 19D(4), 25Cases cited: Australian Competition and Consumer Commission v Dukemaster Pty Ltd [2009] FCA 682; [2009] ATPR 42-290
Australian Competition and Consumer Commission v Jones (No 5) [2011] FCA 49
Australian Competition and Consumer Commission v Jutsen (No 3) (2011) 206 FCR 264
Australian Competition and Consumer Commission v Kaye [2004] FCA 1363
Australian Competition and Consumer Commission v TPG Internet Pty Ltd [2013] HCA 54; (2013) 250 CLR 640
Aspen Pharmacare Australia Pty Ltd v Minister for Health and Ageing [2012] AATA 362
Butcher v Lachlan Elder Realty Pty Ltd (2004) 218 CLR 592
Keep reading for free
Create a free CaseChat account to read Australian Competition and Consumer Commission v Homeopathy... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2014] FCA 1412
- Decision Date
CaseChat Overview and Summary
The court found that the representations made by the respondent were misleading, deceptive or false, and that they were made in trade or commerce and carried on for profit. The court held that the representations about the effectiveness of the vaccine and homeopathic treatments for whooping cough prevention were false and misleading, and that they contravened sections 18 and 29 of the ACL. The court also found that the disclaimers did not erase the misleading, deceptive and false nature of the representations. The court held that the representations were misleading, deceptive or false when read in the context of an epidemic, and that the representations that the vaccine was "short-lived" were misleading, deceptive or false given the vaccine's propensity to wane over time. The court found that the representations about the effectiveness of homeopathic treatments for whooping cough prevention did not fall to be assessed against a homeopathic epistemological framework or orthodox medical science, and that they implied a reasonable basis in medical science.
The court held that the evidence led by the ACCC as to the nature and seriousness of whooping cough, the nature of the vaccine and recommended schedule for its administration and the essential precepts of Evidence Based Medicine were not contentious. The court held that the expert evidence led by the respondent did not comply with the rules of evidence and was therefore inadmissible. The court held that the representations made by the respondent were not contributions to public debate or educational, and that they had the requisite commercial or trading character.
The court made a declaration that the respondent had engaged in conduct in trade or commerce that was misleading and deceptive, or likely to be so, in contravention of section 18 of the ACL. The court also made a declaration that the respondent had made false or misleading representations in trade or commerce that the vaccine was of a particular standard or quality, and that homeopathic treatments were a safe and effective alternative to the vaccine. The court ordered that the matter be listed for directions to set a timetable for any further evidence on the question of penalties and submissions including on the injunctive and other final orders sought by the ACCC.
Orders
Orders of the court
3) The matter is listed for directions at 9.30 am on Wednesday 4 February 2015 in order to set a timetable for any further evidence on the question of penalties and submissions including on the injunctive and other final orders sought by the Applicant.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
In undertaking the balancing exercise required by s 25(1), a high level of safety is required from vaccines, which unlike most medications, are generally given to healthy people, to prevent illness and death. Dr Crawford explained that a fever in the first twenty-four hours is an expected and common side effect from the administration of a vaccine because the vaccine operates to stimulate the system to produce a new protection. 4.3 Administration of the Vaccine under the National Immunisation Program The Vaccine is administered in Australia as part of the National Immunisation Program (NIP), in common with the majority of vaccines. All of the pertussis vaccines under the NIP are acellular pertussis vaccines (“Pa”), containing three or more purified components of B.pertussis. The change from a whole cell pertussis to acellular vaccines took place in the late 1990s. The vaccine is injectable and usually given as part of a combination vaccine including diphtheria (D) and tetanus (T) (“DTPa”), and may also include hepatitis B, polio and Haemophilus influenzae type b. In line with the requirements earlier outlined, the Vaccine had to be approved as a medication by the TGA before it could be included on the NIP. Dr Crawford explained the process following TGA approval by which a vaccine is added to the NIP: The vaccine is then reviewed by the Australian Technical Advisory Group on Immunisation (ATAGI), who will make recommendations about the utility of adding a vaccine to the NIP. The vaccine then requires a cost effectiveness evaluation through the Pharmaceutical Benefits Advisory Committee (PBAC)… This assessment will take into account the efficacy/effectiveness of the vaccine on available evidence and the price proposed by the pharmaceutical company. These recommendations then go to the federal government for approval through the Department of Health in Canberra before a new vaccine can be added onto the NIP. State health departments are involved in the introduction of vaccines onto the NIP program. The pertussis vaccine is generally included in a combined vaccine administered by injection, the type of which varies depending on the recipient’s age. While pertussis vaccination schedules differ around the world, Dr Wood explained that none currently started earlier than six weeks of age. The schedule recommended by the World Health Organisation is six, ten and fourteen weeks for primary immunisation. The recommended schedule in Australia is administration of the vaccine: (a)at 6 – 8 weeks, 4 and 6 months of age (the primary schedule);with boosters at:(b)at 3.5 – 4 years; and(c)during adolescence (11 – 13 years); and(d)adulthood (recommended for those who wish to reduce the likelihood of becoming ill with pertussis, such as parents of young infants, and at 50 years of age);(collectively, “the Vaccine”: see Australian Government Department of Health and Aging, The Australian Immunisation Handbook (10th Ed, 2013) at 4.12.7 (the “Australian Immunisation Handbook”)).